Drug Trial Radar · NCT07177469
UBT251 Injection Phase II Study (Overweight or Obesity)
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
205
Actual
Start
Mar 14, 2025
Primary completion
Oct 22, 2025
Study completion Nov 19, 2025
Sponsor
- Lead sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, double-blind, parallel, placebo-controlled phase II study to evaluate the efficacy and safety of UBT251 Injection in overweight/obese patients
Conditions
- Obesity &Amp; Overweight
Interventions
UBT251 Injection 2.0 mg and UBT251 Injection PlaceboDrug
UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly
UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection PlaceboDrug
UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly
UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection PlaceboDrug
UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly
UBT251 Injection 6.0 mg and UBT251 Injection PlaceboDrug
UBT251 Injection and UBT251 Injection Placebo subcutaneously once weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Body WeightTime frame: Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.